XRF Scientific Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de XRF Scientific de 9.8% y 7.3% por año respectivamente. Se prevé que el BPA crezca en un 9.8% al año. Se espera que la rentabilidad financiera sea de 15.3% en 3 años.

Información clave

9.8%

Tasa de crecimiento de los beneficios

9.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Machinery	51.2%
Tasa de crecimiento de los ingresos	7.3%
Rentabilidad financiera futura	15.3%
Cobertura de analistas	Low
Última actualización	20 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is Now The Time To Look At Buying XRF Scientific Limited (ASX:XRF)?

Feb 12

Returns On Capital Are A Standout For XRF Scientific (ASX:XRF)

Jan 18

Why The 22% Return On Capital At XRF Scientific (ASX:XRF) Should Have Your Attention

Oct 05

An Intrinsic Calculation For XRF Scientific Limited (ASX:XRF) Suggests It's 23% Undervalued

Mar 17

XRF Scientific (ASX:XRF) Strong Profits May Be Masking Some Underlying Issues

Mar 01

Is Now The Time To Put XRF Scientific (ASX:XRF) On Your Watchlist?

Feb 17

Our View On XRF Scientific's (ASX:XRF) CEO Pay

Jan 27

Who Has Been Selling XRF Scientific Limited (ASX:XRF) Shares?

Jan 12

XRF Scientific Limited's (ASX:XRF) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Dec 23

XRF Scientific Limited's (ASX:XRF) Intrinsic Value Is Potentially 22% Below Its Share Price

Dec 10

The Returns At XRF Scientific (ASX:XRF) Provide Us With Signs Of What's To Come

Nov 25

Previsiones de crecimiento de beneficios e ingresos

ASX:XRF - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2026	68	11	10	11	1
6/30/2025	64	10	9	11	1
6/30/2024	59	9	8	9	1
12/31/2023	57	8	7	8	N/A
9/30/2023	56	8	7	8	N/A
6/30/2023	55	8	8	8	N/A
3/31/2023	52	7	5	6	N/A
12/31/2022	49	7	3	4	N/A
9/30/2022	44	7	3	3	N/A
6/30/2022	40	6	3	3	N/A
3/31/2022	37	6	3	4	N/A
12/31/2021	35	6	4	5	N/A
9/30/2021	33	5	4	5	N/A
6/30/2021	31	5	4	5	N/A
3/31/2021	30	5	4	5	N/A
12/31/2020	28	4	5	5	N/A
9/30/2020	29	3	4	5	N/A
6/30/2020	29	3	3	4	N/A
3/31/2020	29	3	3	4	N/A
12/31/2019	30	3	2	3	N/A
9/30/2019	29	2	3	3	N/A
6/30/2019	29	2	3	4	N/A
3/31/2019	28	2	2	2	N/A
12/31/2018	27	2	0	1	N/A
9/30/2018	26	1	0	1	N/A
6/30/2018	24	1	-1	1	N/A
3/31/2018	24	1	-1	1	N/A
12/31/2017	23	1	-1	1	N/A
9/30/2017	22	1	N/A	0	N/A
6/30/2017	22	1	N/A	0	N/A
3/31/2017	22	1	N/A	1	N/A
12/31/2016	22	1	N/A	1	N/A
9/30/2016	21	1	N/A	1	N/A
6/30/2016	21	2	N/A	0	N/A
3/31/2016	20	2	N/A	1	N/A
12/31/2015	20	2	N/A	2	N/A
9/30/2015	20	2	N/A	3	N/A
6/30/2015	21	3	N/A	4	N/A
3/31/2015	21	3	N/A	4	N/A
12/31/2014	22	3	N/A	3	N/A
9/30/2014	22	3	N/A	3	N/A
6/30/2014	22	2	N/A	3	N/A
3/31/2014	21	3	N/A	3	N/A
12/31/2013	20	3	N/A	3	N/A
9/30/2013	21	3	N/A	4	N/A
6/30/2013	23	4	N/A	4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (9.8% al año) de XRF es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: Se prevé que los beneficios (9.8% al año) de XRF crezcan menos que el mercado Australian (13.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de XRF crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (7.3% al año) de XRF crezcan más rápidamente que los del mercado Australian (4.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 7.3% al año) de XRF crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de XRF sea baja dentro de 3 años (15.3%).

XRF Scientific Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased to AU$0.65

Price target increased to AU$0.46

Recent updates

First half 2024 earnings released: EPS: AU$0.033 (vs AU$0.028 in 1H 2023)

Is Now The Time To Look At Buying XRF Scientific Limited (ASX:XRF)?

Returns On Capital Are A Standout For XRF Scientific (ASX:XRF)

New minor risk - Market cap size

Investor sentiment improves as stock rises 15%

Now 22% undervalued after recent price drop

Why The 22% Return On Capital At XRF Scientific (ASX:XRF) Should Have Your Attention

XRF Scientific Limited, Annual General Meeting, Oct 31, 2023

Upcoming dividend of AU$0.033 per share at 3.0% yield

XRF Scientific (ASX:XRF) Is Increasing Its Dividend To A$0.033

XRF Scientific's (ASX:XRF) Upcoming Dividend Will Be Larger Than Last Year's

New minor risk - Dividend sustainability

Full year 2023 earnings: EPS and revenues miss analyst expectations

Do XRF Scientific's (ASX:XRF) Earnings Warrant Your Attention?

XRF Scientific Limited Announces Ordinary Fully Paid Dividend for the Twelve Months Ended June 30, 2023, Payment Date of October 13, 2023

Non-Executive Director recently bought AU$89k worth of stock

New minor risk - Market cap size

Investor sentiment improves as stock rises 19%

Non-Executive Director recently bought AU$61k worth of stock

Investor sentiment improves as stock rises 18%

Now 23% undervalued

First half 2023 earnings released: EPS: AU$0.028 (vs AU$0.021 in 1H 2022)

Does XRF Scientific (ASX:XRF) Deserve A Spot On Your Watchlist?

Insufficient new directors

Now 21% undervalued

XRF Scientific (ASX:XRF) Seems To Use Debt Rather Sparingly

XRF Scientific Limited Announces Dividend That Relates to the Financial Reporting or Payment Period Ended on June 30, 2022, Payable on October 14, 2022

Upcoming dividend of AU$0.025 per share

XRF Scientific Limited, Annual General Meeting, Oct 21, 2022

Full year 2022 earnings released: EPS: AU$0.045 (vs AU$0.038 in FY 2021)

XRF Scientific Limited Announces Fully Franked Ordinary Dividend for the Year Ended June 30, 2022, Payable on 14 October 2022

Now 20% undervalued

We Think XRF Scientific (ASX:XRF) Can Manage Its Debt With Ease

Now 24% undervalued

Price target increased to AU$0.65

Insufficient new directors

XRF Scientific (ASX:XRF) Shareholders Will Want The ROCE Trajectory To Continue

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Is Now The Time To Put XRF Scientific (ASX:XRF) On Your Watchlist?

Upcoming dividend of AU$0.02 per share

Full year 2021 earnings released: EPS AU$0.038 (vs AU$0.023 in FY 2020)

Price target increased to AU$0.46

Non-Executive Director recently bought AU$72k worth of stock

XRF Scientific (ASX:XRF) Is Looking To Continue Growing Its Returns On Capital

Does XRF Scientific (ASX:XRF) Have A Healthy Balance Sheet?

An Intrinsic Calculation For XRF Scientific Limited (ASX:XRF) Suggests It's 23% Undervalued

XRF Scientific (ASX:XRF) Strong Profits May Be Masking Some Underlying Issues

Non-Executive Director recently bought AU$93k worth of stock

New 90-day low: AU$0.28

First half 2021 earnings released: EPS AU$0.018 (vs AU$0.012 in 1H 2020)

Earnings beat expectations, revenue disappoints

Is Now The Time To Put XRF Scientific (ASX:XRF) On Your Watchlist?

Our View On XRF Scientific's (ASX:XRF) CEO Pay

Who Has Been Selling XRF Scientific Limited (ASX:XRF) Shares?

XRF Scientific Limited's (ASX:XRF) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

XRF Scientific Limited's (ASX:XRF) Intrinsic Value Is Potentially 22% Below Its Share Price

The Returns At XRF Scientific (ASX:XRF) Provide Us With Signs Of What's To Come

New 90-day low: AU$0.28

New 90-day high: AU$0.34

Earnings released

New 90-day high - AU$0.30

New 90-day high - AU$0.29

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento